A5025714200- Bone health and osteoporosis research
- Estrogen and related hormone effects
- Bone Metabolism and Diseases
- Bone health and treatments
- Vitamin D Research Studies
- Menopause: Health Impacts and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Hip and Femur Fractures
- Neuropeptides and Animal Physiology
- Parathyroid Disorders and Treatments
- Scoliosis diagnosis and treatment
- Diet and metabolism studies
- Peripheral Artery Disease Management
- Hormonal and reproductive studies
- Spine and Intervertebral Disc Pathology
- Cancer Risks and Factors
- Inflammatory mediators and NSAID effects
- Heart Failure Treatment and Management
- Medical Imaging and Analysis
- Musculoskeletal pain and rehabilitation
- Stress Responses and Cortisol
- Pain Management and Opioid Use
- Fluoride Effects and Removal
- Vitamin K Research Studies
- Adrenal Hormones and Disorders
University of Siena
1991-2024
Eli Lilly (United States)
1998-2016
Helsinki University Hospital
2016
University of Helsinki
2016
University of Oulu
2016
Eli Lilly (Italy)
1999-2012
Eli Lilly (Singapore)
1999
Vrije Universiteit Amsterdam
1997
University of Amsterdam
1996
Glostrup Hospital
1991
Estrogen treatment improves calcium malabsorption induced by surgical or natural menopause, but the mechanisms involved are still under debate, with both increased production of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] and improved peripheral responsiveness to steroid having been proposed. To address this issue, we studied effect short term administration 1,25-(OH)2D3 (1 μg/day for 7 days) on intestinal fractional absorption 47Ca (47Ca FA) vertebral bone density, measured dual photon...
Objective To determine the effect of alendronate (ALN) and teriparatide on trabecular bone score (TBS) in patients with glucocorticoid‐induced osteoporosis. Methods Patients chronic glucocorticoid therapy–induced osteoporosis (median 7.5 mg/day prednisone equivalent for ≥90 days) were randomized to receive oral ALN 10 (n = 214) or subcutaneous 20 μg/day 36 months; 118 group 123 completed treatment. Dual x‐ray absorptiometry (DXA) results 53 receiving 56 who had DXA scans adequate resolution...
Calcitonin gene-related peptide (CGRP) is present in sensory nerve fibers the heart and around peripheral arteries. On interaction with specific CGRP binding sites activation of adenylate cyclase, causes vasodilation has positive inotropic chronotropic effects on heart. In study, human I II exerted isolated right auricles relaxed small arteries from skeletal muscle precontracted norepinephrine (EC50 for 0.59 nM 0.37 nM). (3.2 nmol) administered i.v. to 6 normal subjects actions concomitant...
Using data from a randomized placebo-controlled trial of 10,101 postmenopausal women not selected on the basis osteoporosis, we examined whether effect raloxifene treatment fractures was consistent across categories fracture risk. Treatment with for 5 yr reduced risk clinical vertebral fractures, but nonvertebral irrespective presence or absence factors fracture.In The Raloxifene Use Heart (RUTH) trial, assigned to had lower fractures. However, it is uncertain in this population low BMD...
None of the available osteoporosis therapies have been shown to completely abolish risk fractures. In clinical practice, outcome may be even poorer. 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year them. This incidence is considerably higher than that observed randomized trials, it significantly related poor compliance lack supplementation calcium vitamin D.Osteoporotic one most important...
Journal Article Improved cardiac performance with human calcitonin gene related peptide in patients congestive heart failure Get access C Gennari, Gennari Correspondence to: Professor Fischer Search for other works by this author on: Oxford Academic PubMed Google Scholar R Nami, Nami D Agnusdei, Agnusdei J A Cardiovascular Research, Volume 24, Issue 3, March 1990, Pages 239–241, https://doi.org/10.1093/cvr/24.3.239 Published: 01 1990 history Received: 10 May 1989 Accepted: 31 October
We studied whether oral administration of ipriflavone, a synthetic derivative naturally occurring isoflavones, could prevent bone loss shortly after menopause.Fifty-six women with low vertebral density and postmenopausal age less than five years were randomly allocated to receive either 200 mg three times daily, or placebo. All subjects also received 1,000 elemental calcium daily.Vertebral declined two in taking only (4.9 +/- 1.1%, SEM, p = 0.001), but it did not change those receiving...
We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 and 200 IU) one im dose in eight premenopausal early postmenopausal women. Total serum calcium beta-endorphin revealed significant changes after all four administrations (P less than 0.05). After two highest cAMP increased 10% 35%, respectively All except 50 IU produced increases plasma sCT The areas under concentration-time curves, calculated for period with maximal (i.e. 120-240 min),...